The glaucoma therapeutics market size is projected to reach US$ 8.02 billion by 2031 from US$ 6.24 billion in 2022. The market is expected to register a CAGR of 3.2% in 2021–2031. The development of novel drug delivery methods and combination therapies is likely to remain a key trend in the glaucoma therapeutics market.

Glaucoma Therapeutics Market Analysis

Glaucoma is a group of eye disorders characterized by the gradual loss of nerve tissue that would eventually lead to vision loss if left untreated. Prostaglandin analogs are among the drugs that are highly effective in reducing eye pressure by promoting better drainage from the eye. The surging prevalence of glaucoma and increasing product launches are expected to favor the glaucoma therapeutics market growth.

Glaucoma Therapeutics Market Overview

The aging population worldwide has led to an increasing incidence of glaucoma, creating a significant opportunity for the glaucoma treatment market growth. The demand for innovative therapies and management strategies is rising due to the higher susceptibility of the aging demographic to the disease. Additionally, the importance of regular eye check-ups for early detection and management of glaucoma has increased patient engagement and demand for advanced treatments. As healthcare systems cater to the needs of an aging population, investments in glaucoma research, development, and access to care are expected to fuel market growth in the coming years.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Glaucoma Therapeutics Market: Strategic Insights

Glaucoma Therapeutics Market

• 
  CAGR (2021 - 2031)

  3.2%
• Market Size 2022
  US$ 6.24 Billion
• Market Size 2031
  US$ 8.02 Billion

Market Dynamics

GROWTH DRIVERS

• Rising Prevalence of Glaucoma Driving the Glaucoma Therapeutics Market

FUTURE TRENDS

• Technological Advancements in Glaucoma Therapeutics will be the Glaucoma Therapeutics Market

OPPORTUNITIES

• Strategies by Major Market Players to Expand Presence in Emerging Markets

Key Players

• Alcon AG
• AbbVie Inc
• Bausch & Lomb Inc
• Fera Pharmaceuticals, LLC
• Viatris Inc
• Novartis AG
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd
• Thea Pharma Inc
• Santen Pharmaceutical Co., Ltd.

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Drug Class

• Beta Blockers
• Alpha Adrenergic Agonists
• Prostaglandins Analogues
• Carbonic Anhydrase Inhibitors
• Combination Drugs

Drug Class

• Beta Blockers
• Alpha Adrenergic Agonists
• Prostaglandins Analogues
• Carbonic Anhydrase Inhibitors
• Combination Drugs

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Glaucoma Therapeutics Market Drivers and Opportunities

Mounting Glaucoma Disease to Favor Market

As per the Glaucoma Research Foundation, in 2022, ~ 80 million were affected with glaucoma globally. In 2010, nearly 8.4 million people worldwide had lost their vision due to primary open-angle glaucoma. According to the Glaucoma Research Foundation, the number is projected to increase to 22 million by 2040. This is expected to increase demand for treatments for glaucoma in the coming period. Propelling incidences of glaucoma among the global population are a major driver of the global glaucoma therapeutics market.

Development of Wearable Technologies – An Opportunity in Customization of Glaucoma Therapeutics

Glaucoma is a major cause of blindness, and early detection and treatment are vital. Wearable glaucoma diagnostics and therapeutics have emerged as potential solutions. Conventional diagnostic techniques provide reliable intraocular pressure data, but emerging contact lenses such as Sensimed Triggerfish offer continuous IOP tracking. For therapy, drug-eluting contact lenses are emerging as a potential solution. Theranostic platforms combine diagnostic and therapeutic capabilities into a single device to offer real-time monitoring and personalized medication dosing.

Glaucoma Therapeutics Market Report Segmentation Analysis

Key segments that contributed to the derivation of the glaucoma therapeutics market analysis are drug class, indication, and distribution channel.

• Based on drug class, the glaucoma therapeutics market is divided into beta blockers, alpha-adrenergic agonists, prostaglandins analogs, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogs segment held the largest market share in 2023.
• The market is segmented by indication into open angle glaucoma, angle closure glaucoma, and others. The open-angle glaucoma segment held the largest share of the market in 2023.
• In terms of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2023. 

Glaucoma Therapeutics Market Share Analysis by Geography

The geographic scope of the glaucoma therapeutics Market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

In 2022, nearly 2.7 million Americans were affected by open-angle glaucoma; glaucoma was the leading cause of irreversible blindness in the US. Due to rising incidences of glaucoma in the region, North America held the largest share in 2022. The growing proclivity toward novel combination therapies and minimally invasive glaucoma treatments and the presence of key market players in North America are factors contributing to the growth of the glaucoma therapeutics market in the region.

Glaucoma Therapeutics Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Glaucoma Therapeucs Market News and Recent Developments

The glaucoma therapeutics market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for glaucoma therapeutics:

• The US Food and Drug Administration (FDA) approved Glaukos Corporation’s New Drug Application (NDA) for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). (Source: Glaukos Corporation, Company News, 2023)
• Alcon announced the acquisition of Aerie Pharmaceuticals, Inc. Through the transaction, the company acquired Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, along with AR-15512, a Phase 3 product candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates. Rocklatan and Rhopressa are Rho-kinase inhibitors indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. The acquisition is expected to broaden Alcon’s portfolio across glaucoma, retina, and ocular surface disease. (Source: Alcon, Press Release, 2022)

GLAUCOMA THERAPEUTICS Market Report Coverage and Deliverables

The “Glaucoma Therapeutics Market Size and Forecast (2022–2031)” report provides a detailed analysis of the market covering below areas:

• Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Market dynamics such as drivers, restraints, and key opportunities
• Key future trends
• Detailed PEST and SWOT analysis
• Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
• Detailed company profiles